Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01339208 · ClinicalTrials.gov registry record · NA

TREAT (Telemedicine for Reach, Education, Access, and Treatment)

A NA study of Type 2 Diabetes, sponsored by University of Pittsburgh.

Completed
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT01339208 is a NA study of Type 2 Diabetes that has completed, run by University of Pittsburgh. The registered enrollment target is 35 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01339208, a NA study of Type 2 Diabetes, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the feasibility and clinical efficacy of an innovative care model that combines Telemedicine consultations, educator therapeutic management and diabetes education to empower patients to be in greater control of their own diabetes care for improvements in diabetes outcomes.

Conditions Studied

Interventions

  • OTHER Telemedicine diabetes intervention

Study Locations (1)

Pennsylvania

  • UPMC Northwest - Seneca

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2011-06
Est. Completion 2015-03
Phase NA

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT01339208

The ClinicalTrials.gov registry entry for NCT01339208 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Telemedicine diabetes intervention is the first listed.

NCT01339208 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01339208 about?

NCT01339208 is a clinical study titled "TREAT (Telemedicine for Reach, Education, Access, and Treatment)". The purpose of this study is to evaluate the feasibility and clinical efficacy of an innovative care model that combines Telemedicine consultations, educator therapeutic management and diabetes education to empower patients to be in greater control of their own diabetes care for improvements in diab...

What is the current status of trial NCT01339208?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2011-06. Estimated completion is 2015-03.

What conditions does trial NCT01339208 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT01339208?

The interventions under investigation include: Telemedicine diabetes intervention (OTHER).

Who is sponsoring clinical trial NCT01339208?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01339208 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.